Tempest Therapeutics, Inc. (NASDAQ: TPST) recently captivated investors with an unprecedented surge of over 3,000% in less than a week. What was the cause of this massive surge in price appreciation? Let’s breakdown the events that provided the fuel for this run in Tempest shares.
Tempest is a front-runner in oncology therapeutics, which unveiled groundbreaking results in the combat against Hepatocellular Carcinoma (HCC) with TPST-1120. This is monumental, given HCC’s standing as one of the most formidable cancers worldwide.
Breakthrough in HCC Treatment
The latest data reveals the paramount potential of TPST-1120 combined with atezolizumab + bevacizumab over the current standard of care for HCC. The significance lies in:
- Increased Response Rate: The TPST-1120 arm achieved a 30% confirmed ORR, substantially outperforming the 13.3% in the control arm.
- Enhanced Patient Retention: Remarkably, 40% of patients on the TPST-1120 arm continue their treatment, in comparison to the 16.7% in the control group.
- Promising Biomarker Data: For patients with a beta-catenin mutation, the TPST-1120 arm reported a confirmed ORR of 43% and DCR of 100%. Additionally, in PD-L1 negative patients, the TPST-1120 arm saw a confirmed ORR of 27%, compared to the 7% in the control group.
Why This is a Game-Changer
The superior clinical outcomes when integrating TPST-1120 with atezolizumab and bevacizumab can potentially revolutionize the standard care for patients with unresectable or metastatic HCC. This therapeutic approach offers:
- More Comprehensive Treatment: TPST-1120 impacts tumor cell metabolism directly and modulates immune suppressive cells and angiogenesis in the tumor surroundings.
- Potential for Pivotal Study: Stephen Brady, CEO of Tempest Therapeutics, expressed enthusiasm regarding advancing TPST-1120 into a pivotal study, considering the significant improvement it showcased over standard care.
Battling Hepatocellular Carcinoma (HCC)
HCC is an aggressive cancer form, with predictions estimating it as the third leading cause of cancer death by 2030. Approximately 900,000 global HCC diagnoses occur annually, with its menace most prominent in East Asia. Factors like chronic liver diseases, hepatitis infections, and alcohol-related liver ailments contribute majorly to HCC. With the majority of early-stage HCC patients facing recurrence after surgery, a reliable therapeutic solution is of utmost importance.
About Tempest Therapeutics
Tempest Therapeutics, stationed in Brisbane, California, is pioneering the journey towards innovative oncology treatments. Their advanced small molecules tackle both tumor and immune mechanisms, exhibiting potential against various tumors. With TPST-1120 and TPST-1495 as their prime clinical programs, Tempest continues its journey of scientific innovation. More insights into their groundbreaking work can be found on their official website.
In conclusion, the latest revelations by Tempest Therapeutics underscore the potential of TPST-1120 in reshaping the HCC treatment landscape. The marked clinical improvements observed in this study signify a hopeful path towards enhancing HCC patient outcomes and overall survival.
Disclosure: Neither Matt Rego nor Spotlight Growth have any position or relationship with any companies mentioned in this article. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.